ELAN Corporation is to distribute Zonisamide, an anti-epileptic drug, in North America which could generate annual sales of between $25 million (£16.5 million) and $40 million, in three to five years time. This follows the signing of an agreement with Dainippon Pharmaceutical which has supplied the drug to the Japanese market since 1989. Dainippon now generates $21 million sales in the Japanese market, representing a 10 per cent share of the epileptic drug market.